References
- Media centre. Depression. Fact sheet N°369, October 2012. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/index.html [cited 17 November 2013].
- Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 435–54.
- Aley KO, Kulkarni SK. GABA-mediated modification of despair behavior in mice. Naunyn Schmiedebergs Arch Pharmacol. 1989; 339: 306–11. [PubMed Abstract].
- Nagatani T, Yamamoto T, Sugihara T, Ueki S. The effect of agonists at the GABA-benzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test. Eur J Pharmacol. 1987; 142: 17–22.
- Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011; 16: 383–406.
- Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand. Suppl. 2011; 192: 5–15.
- Costa E. From GABAA receptor diversity emerges a unified vision of GABAergic inhibition. Annu Rev Pharmacol Toxicol. 1998; 38: 321–50.
- Wamsley JK, Longlet LL, Hunt ME, Mahan DR, Alburges ME. Characterization of the binding and comparison of the distribution of benzodiazepine receptors labeled with [3H]diazepam and [3H]alprazolam. Neuropsychopharmacology. 1993; 8: 305–14.
- Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000; 131: 1251–4.
- Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977; 266: 730–2.
- Bale TL, Vale WW. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous response. J Neurosci. 2003; 23: 5295–301. [PubMed Abstract].
- Fernández-Teruel A, Escorihuela RM, Boix F, Tobeña A. Picrotoxin changes the effects of imipramine and desipramine in rats in the forced swimming test. Eur J Pharmacol. 1990; 181: 35–41.
- Rudolph U, Möhler H. Review GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol. 2006; 6: 18–23.
- Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012; 62: 42–53.
- Atack JR. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr Top Med Chem. 2011; 11: 1203–14.
- Engin E, Liu J, Rudolph U. α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. Pharmacol Ther. 2012; 136: 142–52.
- Broderick PA. Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21: 1117–40.
- Maejima T, Masseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. Front Integr Neurosci. 2013; 7: 40.
- Tao R, Ma Z, Auerbach SB. Differential regulation of 5-hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats. Br J Pharmacol. 1996; 119: 1375–84.